
AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Amkor, you really have to buy into its role as a key outsourced packaging and test partner in AI and high‑performance computing, not just a cyclical chip subcontractor. The latest quarterly dividend affirmation at US$0.08352 per share reinforces a message of capital discipline and balance sheet confidence, but it does not materially change the near‑term story that has driven the recent 18% share price pullback: soft patches in Communications and elevated capital spending as Amkor builds out its Arizona campus. The more meaningful shift in catalysts and risks comes from the expanding pipeline tied to TSMC and NVIDIA, which could tighten utilization and support earnings if those programs ramp as planned, while also increasing execution risk, customer concentration exposure and the financial burden of staying ahead in advanced packaging.
However, there is one concentration risk in particular that investors should keep front of mind. Amkor Technology's shares have been on the rise but are still potentially undervalued by 41%. Find out what it's worth.Explore 6 other fair value estimates on Amkor Technology - why the stock might be worth less than half the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com